Related Experiment Video
Updated: Apr 19, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.4K
Pharmacogenetics of SULT1A1
Jaclyn Daniels1, Susan Kadlubar
1University of Arkansas for Medical Sciences, COM Department of Medical Genetics, 4301 W. Markham, #580 Little Rock, AR 72205, USA.
Pharmacogenomics
|December 11, 2014
Summary
Genetic variations in sulfotransferase 1A1 (SULT1A1) impact drug efficacy and cancer risk. Understanding these genetic differences is key to personalized medicine and cancer prevention strategies.
Area of Science:
- Pharmacogenetics
- Biochemistry
- Cancer Research
Background:
- Sulfotransferase 1A1 (SULT1A1) is crucial for metabolizing endogenous compounds and xenobiotics.
- Genetic variations, including single nucleotide polymorphisms (SNPs), affect SULT1A1 activity and vary across ethnic groups.
- Previous research primarily focused on the SULT1A1*1/2 SNP, overlooking other potentially significant variants.
Purpose of the Study:
- To review the impact of SULT1A1 genetic variations beyond the SULT1A1*1/2 SNP.
- To explore how these variants influence the efficacy of anticancer drugs.
- To connect SULT1A1 genetic variability to environmental and dietary exposures in cancer development and prevention.
Main Methods:
- Literature review of studies on SULT1A1 genetic variability.
- Analysis of research linking SULT1A1 variants to drug metabolism and cancer susceptibility.
- Synthesis of findings on the role of SULT1A1 in response to anticancer therapies and environmental exposures.
Main Results:
- SULT1A1 genetic variants, not just SULT1A1*1/2, can significantly alter enzyme activity.
- These variations influence individual responses to various anticancer agents.
- Differential metabolism by SULT1A1 variants affects susceptibility to and protection from cancers.
Conclusions:
- SULT1A1 genetic variability plays a critical role in personalized cancer therapy.
- Understanding SULT1A1 genotypes can guide treatment decisions and cancer prevention strategies.
- Further research is needed to fully elucidate the complex interplay between SULT1A1 genetics, environmental factors, and cancer outcomes.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
168
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
168
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
01:27Pharmacogenetics of Drug Metabolism: Overview
170
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
170
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
83
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
83
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
286
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
286
01:27Principles of Pharmacogenetics: Types of Genetic Variants
121
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
121